USO 20345

A PHASE 1/3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF SELINEXOR, A SELECTIVE INHIBITOR OF NUCLEAR EXPORT, IN COMBINATION WITH RUXOLITINIB IN TREATMENT-NAIVE PATIENTS WITH MYELOFIBROSIS (XPORT-MF-034)

Disease Types: Hematology

Available at:

• Norfolk (Brock Cancer Center)
• Virginia Beach (Princess Anne)